Skip to main content
. 2018 Oct 6;12(6):803–812. doi: 10.1007/s11764-018-0717-5

Table 1.

Unadjusted and adjusted odds ratios (cancer compared with control) of meeting quality measures

Quality measure Cohort
Combined Breast cancer Colorectal cancer Prostate cancer
Unadjusteda Adjustedb Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
Blood pressure ≤ 150/90 mmHg
 Odds ratioc 1.02 1.05 0.96 1.00 0.96 0.96 1.14 1.16*
 95% CI (0.93–1.13) (0.96–1.16) (0.81–1.14) (0.85–1.18) (0.81–1.14) (0.81–1.13) (0.97–1.13) (1.00–1.35)
Blood pressure ≤ 140/80 mmHg
 Odds ratio 1.02 1.04 1.00 1.06 1.00 0.99 1.04 1.06
 95% CI (0.94–1.10) (0.97–1.12) (0.87–1.15) (0.93–1.20) (0.88–1.14) (0.87–1.11) (0.92–1.18) (0.95–1.19)
Total cholesterol ≤ 5 mmol/L
 Odds ratio 0.81*** 0.82*** 0.95 1.03 0.85 0.80** 0.66*** 0.66***
 95% CI (0.73–0.89) (0.75–0.90) (0.80–1.15) (0.88–1.21) (0.72–1.01) (0.68–0.93) (0.57–0.77) (0.57–0.76)
Albumin creatinine ratio test
 Odds ratio 0.81*** 0.83*** 0.78** 0.80** 0.81* 0.81* 0.84* 0.86
 95% CI (0.73–0.89) (0.75–0.91) (0.65–0.92) (0.68–0.95 0.67–0.97) (0.68–0.97) (0.72–0.99) (0.73–1.01)
ACE-I or ARBd
 Odds ratio 0.64 0.48 0.85 0.57 0.81 0.76 0.44 0.33
 95% CI (0.30–1.35) (0.21–1.10) (0.13–5.75) (0.05–5.98) (0.26–2.60) (0.23–2.56) (0.14–1.43) (0.09–1.14)
HbA1c ≤ 59 mmol/mol
 Odds ratio 0.80*** 0.77*** 0.74** 0.72*** 0.79* 0.80* 0.86 0.79**
 95% CI (0.72–0.89) (0.70–0.85) (0.60–0.90) (0.61–0.85) (0.65–0.97) (0.68–0.95) (0.72–1.02) (0.68–0.92)
HbA1c ≤ 64 mmol/mol
 Odds ratio 0.78*** 0.75*** 0.76** 0.74*** 0.76** 0.77** 0.80* 0.73**
 95% CI (0.70–0.87) (0.68–0.82) (0.62–0.93) (0.63–0.88) (0.63–0.93) (0.65–0.91) (0.67–0.95) (0.63–0.85)
HbA1c ≤ 75 mmol/mol
 Odds ratio 0.81*** 0.80*** 0.86 0.86 0.74** 0.76** 0.83* 0.79**
 95% CI (0.73–0.91) (0.73–0.89) (0.70–1.05) (0.72–1.03) (0.60–0.90) (0.63–0.91) (0.70–1.00) (0.67–0.93)
Influenza immunization
 Odds ratio 1.26* 1.31**†↑ 0.93 0.95 0.98 0.96 2.04*** 2.18***
 95% CI (1.03–1.53) (1.07–1.59) (0.66–1.31) (0.68–1.34) (0.69–1.39) (0.67–1.36) (1.46–2.86) (1.56–3.06)
Retinal screening
 Odds ratio 0.96 0.99 1.01 1.03 1.00 1.03 0.89 0.91
 95% CI (0.88–1.05) (0.91–1.08) (0.87–1.18) (0.88–1.19) (0.85–1.18) (0.88–1.20) (0.77–1.03) (0.79–1.05)
Foot exam
 Odds ratio 0.79** 0.94 0.75* 0.88 0.76* 0.92 0.93 1.03
 95% CI (0.68–0.92) (0.85–1.04) (0.57–0.98) (0.74–1.04) (0.58–0.99) (0.78–1.09) (0.71–1.21) (0.87–1.21)
Dietary review
 Odds ratio 0.85 1.01 0.77 0.89 0.87 1.02 0.98 1.08
 95% CI (0.70–1.03) (0.87–1.16) (0.53–1.13) (0.66–1.21) (0.66–1.14) (0.80–1.28) (0.69–1.39) (0.83–1.41)
Asked about erectile dysfunction
Odds ratio 0.94 1.06 NA NA 0.86 1.00 1.02 1.08
95% CI (0.77–1.16) (0.89–1.26) NA NA (0.64–1.15) (0.75–1.32) (0.78–1.34) (0.86–1.35)
Advice about erectile dysfunction
 Odds ratio 1.55* 1.60** NA NA 1.17 1.26 1.68** 1.71**
 95% CI (1.09–2.19) (1.18–2.18) NA NA (0.65–2.11) (0.71–2.26) (1.14–2.48) (1.21–2.41)

ACE-I angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, HbA1c glycosylated hemoglobin, NA not applicable

*p < 0.05, **p < 0.01, ***p < 0.001

Remained statistically significant after Benjamini-Hochberg adjustment for multiple comparisons

Goodness of fit of the model was significantly improved by adding an interaction term for time versus cancer, and interaction term indicates effect of cancer over time was to increase the adjusted odds of the outcome measure in the cancer group

aThe multilevel logistic regression models for the unadjusted odds ratios also included time (years) as a factor variable and a random effect for the patient

bThe regression models for the adjusted odds ratios also included age, sex (combined cohorts, colorectal cancer), year of index date, smoking status, drinking status, body mass index, Charlson Comorbidity Index, Index of Multiple Deprivation score, baseline blood pressure, baseline total cholesterol, baseline HbA1c, history of one or more microvascular complications of diabetes, history of one or more macrovascular complications of diabetes, and history of diabetes medications

cOdds ratios: cancer compared to control

dIn patients diagnosed with nephropathy or microalbuminuria